Close
CDMO Safety Testing 2026
Novotech

Sydney Applauds NSW Financing For Biomedical Research Hub

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing...
- Advertisement -

The University of Sydney has revealed that the New South Wales (NSW) state will contribute $143.3 million over four years to the construction of a world-class health and technology centre in Sydney. The Sydney Biomedical Accelerator (SBA) will be a cutting-edge biomedical research facility that will combine fundamental, clinical, and patient-centered studies to accelerate real-world healthcare outcomes. It will be a collaboration between the NSW Government, Sydney Local Health District, and University of Sydney, as well as a premier medical research facility, the Centenary Institute, and will be housed within the Tech Central area.

As part of a hospital, university, and technological innovation ecosystem, the SBA will offer a different global density of biomedical research expertise and research resources, and will be poised to dynamically work with industry and start-ups. Professor Robyn Ward of the University’s Faculty of Medicine and Health said the Sydney Biomedical Accelerator would foster collaborative efforts among world-class doctors, scientists, engineers, computer scientists, entrepreneurs, and research and industry partners.

The Sydney Biomedical Accelerator will begin construction this year, with initial occupancy scheduled for 2026.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing...

The Push for Greater Accuracy in Clinical Trials

Clinical trials are the foundation of modern medicine. Every...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป